Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP

Q: What equity awards did Amneal (AMRX) grant to Jason B. Daly?

Jason B. Daly received two equity awards : 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Amneal’s Class A common stock, subject to time-based or performance-based vesting conditions tied to future dates and stock price targets.

Q: How do the restricted stock units for Jason B. Daly at AMRX vest?

The time-based restricted stock units vest in four equal annual installments starting on March 2, 2027. This means one-quarter of the 65,359 units becomes payable in shares each year over four years, assuming continued service and satisfaction of any applicable conditions.

Q: How are Jason B. Daly’s performance-based RSUs at Amneal structured?

The performance-based RSUs cover a target of 65,359 shares and vest based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. The actual payout can range from 0% to 200% of target, depending on performance outcomes.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Daly Jason B. reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals reported that EVP and Chief Legal Officer Jason B. Daly received two equity awards on March 2, 2026. He was granted 65,359 restricted stock units that vest in four equal annual installments beginning March 2, 2027. He also received 65,359 performance-based restricted stock units tied to three-year stock price targets, with any earned units vesting on February 28, 2029.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Daly Jason B.

Role EVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	65,359	$0.00	--
Grant/Award	Performance-Based Restricted Stock Units	65,359	$0.00	--

Holdings After Transaction: Restricted Stock Units — 65,359 shares (Direct); Performance-Based Restricted Stock Units — 65,359 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly Jason B.

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/02/2026		A		65,359		⁽²⁾	⁽²⁾	Class A Common Stock	65,359	$0	65,359	D
Performance-Based Restricted Stock Units	⁽³⁾	03/02/2026		A		65,359		⁽⁴⁾	⁽⁴⁾	Class A Common Stock	65,359	$0	65,359	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

4. Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Amneal (AMRX) grant to Jason B. Daly?

Jason B. Daly received two equity awards: 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Amneal’s Class A common stock, subject to time-based or performance-based vesting conditions tied to future dates and stock price targets.

How do the restricted stock units for Jason B. Daly at AMRX vest?

The time-based restricted stock units vest in four equal annual installments starting on March 2, 2027. This means one-quarter of the 65,359 units becomes payable in shares each year over four years, assuming continued service and satisfaction of any applicable conditions.

How are Jason B. Daly’s performance-based RSUs at Amneal structured?

The performance-based RSUs cover a target of 65,359 shares and vest based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. The actual payout can range from 0% to 200% of target, depending on performance outcomes.

When do Jason B. Daly’s performance-based RSUs at AMRX vest if earned?

Any earned performance-based restricted stock units vest in full on February 28, 2029, which is the last day of the three-year performance period. The number of shares ultimately delivered depends on whether the specified stock price targets have been achieved during that period.

What does each RSU awarded to Jason B. Daly at Amneal represent?

Each restricted stock unit and performance-based restricted stock unit represents a contingent right to receive one share of Amneal Pharmaceuticals’ Class A common stock. Shares are only delivered if the applicable time-based vesting schedule or performance conditions are satisfied by the relevant vesting dates.

Can Jason B. Daly receive more than 65,359 shares from his performance-based RSUs at AMRX?

Yes, the performance-based RSU award can pay out up to 200% of target. While 65,359 is the target share amount, the actual shares delivered after the three-year performance period can range from zero up to double that target, depending on stock price performance.